# CORCEPT THERAPEUTICS INC (CORT) · Edgar & Edgarette company card

> Corcept Therapeutics (CORT) grew revenue 12.8% in FY2025 to $761 million, operating margin 5.9% against a -3.8% median for pharmaceutical preparations, equity 77.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1088856 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CORT) · [JSON](https://www.pops4.com/boards/company/CORT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $761M |
| Revenue growth, 1 year | 12.8% |
| Revenue growth per year | 20.1% |
| Operating margin | 5.9% (prior year 20.3%) |
| Net margin | 13.1% |
| Operating cash flow | $142M |
| Capital spending | $211,000 |
| Free cash flow | $142M |
| Cash | $120M |
| Long-term debt | — |
| Total assets | $837M |
| Total equity | $648M |
| Equity ÷ assets | 77.4% |
| Return on equity | 15.4% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 8.97 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.81 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $761.4M (FY2025). Experience: revenue up 12.8% on the year, up 20.1% a year over 4 years; operating margin 5.9%, down from 20.3%. Soundness: equity 77.4% of assets, return on equity 15.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $742.9M and $1.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $680.7M to $1.1B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 5.9% against a -3.8% median; growth 12.8% against 13.7%.

Range logged 2026-09-24, receipt bcf7009ffb2d87d0, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-09-23 ([filing](https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/0001193125-26-398561-index.htm))

## Recent filings

- 8-K · filed 2026-09-23 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/0001193125-26-398561-index.htm)
- 10-Q · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050613/0001628280-26-050613-index.htm)
- 8-K · filed 2026-07-29 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/0001628280-26-050607-index.htm)
- 8-K · filed 2026-06-17 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/0001193125-26-274258-index.htm)
- 8-K · filed 2026-06-03 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000119312526254622/0001193125-26-254622-index.htm)
- 8-K · filed 2026-05-28 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/0001628280-26-038793-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001088856.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1088856

## Cite

POPS4, Edgar & Edgarette: CORCEPT THERAPEUTICS INC (CORT) company card, from the company's own SEC filings, accessed 2026-11-02, https://www.pops4.com/boards/company/CORT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.